Products are for research use only, not for human use

Guides

GLOW vs KLOW: GHK-Cu + BPC-157 + TB-500 vs the Four-Peptide KPV Blend

GLOW and KLOW share GHK-Cu, BPC-157 and TB-500; KLOW adds KPV. What each vial holds by mass and by molecule count, what the copper does, which TB-500 is in the blend, and how a four-component lot is verified.

Marcus Hopkin, PhD, Director of Research and Development at Volta Peptides.

Written by Marcus Hopkin, PhD

Director of Research and Development, Volta Peptides

November 20, 202619 min read

Key Takeaways

  • •KLOW is GLOW plus 10 mg of KPV. GLOW holds GHK-Cu, BPC-157 and TB-500 at 50 + 10 + 10 mg (70 mg). KLOW adds KPV for 80 mg.
  • •Both are GHK-Cu blends first. GHK-Cu is 71% of a GLOW vial and 63% of a KLOW vial by mass, and by number of molecules it is 87% and 72%.
  • •By molecule count, KPV is not a minor partner. At 342 g/mol it supplies about 29 µmol in a KLOW vial, more than BPC-157 and TB-500 combined.
  • •Copper stays on GHK. Of the four components only GHK has the histidine-based site that holds copper(II) tightly, and none of the other three carries a methionine, cysteine or tryptophan for copper to oxidise.
  • •The blend itself has never been studied. No published trial or animal study tests either vial; a 2026 rat study of BPC-157 and TB-500 together reported no added effect over either alone.
  • •A blend is verified component by component. The KLOW lot we publish measured 95.50 mg of peptide across four components, each between 99.59% and 99.81% purity.

Summary

GLOW and KLOW differ by one component: KLOW adds 10 mg of the alpha-MSH fragment KPV to the GHK-Cu, BPC-157 and TB-500 that both share. Most of each vial is GHK-Cu, by mass and even more by molecule count, which means a single purity figure for a blend mostly describes the GHK-Cu peak. Neither blend has been studied as a mixture, so everything known about them comes from studies of the separate compounds. To know what a vial really holds, look for a report that identifies and quantifies every component on its own and confirms which TB-500 molecule was used.

GLOW and KLOW are the retail names for two fixed-ratio peptide blends that share three components. GLOW is GHK-Cu, BPC-157 and TB-500 at 50 + 10 + 10 mg, 70 mg in total. KLOW is the same three plus 10 mg of the tripeptide KPV, 80 mg in total. That one extra component is the entire difference in composition, and most of what is written about the pair stops there. This guide goes further: what each vial holds by mass and by number of molecules, what the copper does in a vial shared with three other peptides, which "TB-500" is actually in the blend, what the published literature has and has not tested, how a four-component vial is verified, and where both stand with Health Canada and the FDA.

It is written for laboratory and in-vitro research procurement. It reports what published studies recorded because that is the public evidence base, and it contains no dosing, administration or human-use guidance, and none should be inferred.

The Short Answer

GLOW is three peptides in one vial and KLOW is the same three plus KPV. If a research design has no use for KPV, the two are the same material. If it does, KLOW supplies KPV at a fixed one-eighth of the vial's mass, and the single compounds are the only way to set that amount, or any other ratio, independently.

What Is in Each Vial

ComponentGLOW (70 mg)KLOW (80 mg)Share of GLOW by massShare of KLOW by mass
GHK-Cu50 mg50 mg71.4%62.5%
BPC-15710 mg10 mg14.3%12.5%
TB-50010 mg10 mg14.3%12.5%
KPVnone10 mg0%12.5%
Total70 mg80 mg

These are label fills. In our catalogue the two vials are listed by composition, as GHK-Cu + BPC-157 + TB-500 70mg and GHK-Cu + KPV + BPC-157 + TB-500 80mg. Other suppliers sell vials under the same retail names with different ratios, and at least one published comparison lists GLOW at 20 + 20 + 30 mg, so the name alone does not establish the composition. Read the per-component fill on the label or the certificate.

Mass Is Not the Same as Molecules

Every comparison of these blends describes them by milligrams. Milligrams hide how many molecules of each component are present, because the four peptides differ in size by a factor of four. Dividing each fill by its molecular weight gives the amount of substance:

ComponentMolecular weight usedIn the vialShare of GLOW by moleculesShare of KLOW by molecules
GHK-Cuabout 402 g/mol (copper complex)124.4 µmol87.2%72.4%
BPC-1571,419.5 g/mol7.0 µmol4.9%4.1%
TB-500 (Ac-LKKTETQ)889.0 g/mol11.2 µmol7.9%6.5%
KPV342.4 g/mol29.2 µmolnot present17.0%

Three things follow. A GLOW vial holds about 18 times as many GHK-Cu molecules as BPC-157 molecules, not five times, as the mass ratio suggests. In KLOW, KPV is the second most numerous molecule in the vial, outnumbering BPC-157 four to one, although it is only an eighth of the mass. And copper is a measurable part of the material: at about 15.8% of the complex's mass, 50 mg of GHK-Cu carries roughly 7.9 mg of copper(II).

Two caveats keep these figures honest. They assume the label fills, and the lot we publish carries more of every component than its label states (see below). And they assume each peptide is weighed as the free peptide or the copper complex; a supplier that weighs a salt form, an acetate for example, puts slightly fewer peptide molecules in the vial. These are chemistry figures for comparing the two materials, not amounts for any use.

The Four Components, One at a Time

ComponentWhat it isResiduesMolecular weightOrigin
GHK-CuCopper(II) complex of the tripeptide Gly-His-Lys3340.4 g/mol for GHK, about 402 g/mol as the copper complexIsolated from human plasma in the 1970s; also a cosmetic ingredient under the INCI name copper tripeptide-1
BPC-157Synthetic pentadecapeptide, GEPPPGKPADDAGLV151,419.5 g/molA partial sequence of a protein described in gastric juice ("body protection compound")
TB-500The acetylated fragment Ac-LKKTETQ7889.0 g/mol (CAS 885340-08-9)Residues 17 to 23 of thymosin beta-4, its actin-binding motif
KPVTripeptide Lys-Pro-Val3342.4 g/molResidues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH)

Two of the four are tripeptides and one is a seven-residue fragment, so both blends are mostly small molecules. Only BPC-157 is a mid-sized peptide. Each single compound has its own overview: GHK-Cu, BPC-157, TB-500 and KPV, and the four-component blend has its own at GHK-Cu + KPV + BPC-157 + TB-500.

What KPV Adds

KPV is the C-terminal tripeptide of alpha-MSH. It is a fragment of the hormone, not a melanocortin receptor agonist in the way full-length alpha-MSH is, and that distinction is the most common error in writing about it. The published work is preclinical: in cell and mouse models of intestinal inflammation, KPV was taken up through the PepT1 peptide transporter and reduced inflammatory signalling readouts, including the NF-kB pathway (Dalmasso et al., Gastroenterology 2008; Kannengiesser et al., Inflammatory Bowel Diseases 2008). No clinical trial has tested it. The regulatory history and the chemistry are set out in what is KPV peptide.

For the choice between the blends, the molecule count matters more than the mass. KPV is 12.5% of a KLOW vial by weight and 17% by molecules, so it is not a trace additive. If KPV is the variable a design is studying, KPV on its own gives control over its amount that a fixed blend cannot.

Copper in a Vial With Three Other Peptides

A question no comparison asks is what the copper does once four peptides share a vial and, later, a solution.

GHK holds copper tightly, and the others hardly at all. GHK binds copper(II) through its N-terminal amine, the imidazole of its histidine and a deprotonated backbone amide, a site whose very high affinity has been measured by calorimetry (Trapaidze, Hureau, Bal and colleagues, Journal of Biological Inorganic Chemistry 2012). None of the other three peptides has a histidine: BPC-157 is GEPPPGKPADDAGLV, the TB-500 fragment is Ac-LKKTETQ and KPV is Lys-Pro-Val. Their carboxylates and amines can coordinate copper only weakly, so in a shared solution the copper is expected to stay on GHK rather than redistribute across the blend.

The other components are poor targets for copper-driven oxidation. Copper(II) can catalyse oxidation of easily oxidised residues, and the usual targets are methionine, cysteine and tryptophan. None of the four peptides contains any of them. That does not make the blend inert, since hydrolysis and aggregation still apply, but it removes the most common copper-specific failure route.

The blue colour is a copper signal, not a quality signal. Copper(II) complexes absorb red light and look blue, so both blends are blue because GHK-Cu dominates them. A vial with no blue tint at all is worth questioning, because it may hold little copper complex. A deep blue proves nothing about the other three components, which are colourless.

Which TB-500 Is in the Blend

"TB-500" is a trade name, not a defined molecule, and it is sold as two different things:

Sold as "TB-500"SizeApproximate mass
Acetylated fragment Ac-LKKTETQ (thymosin beta-4 residues 17 to 23)7 residues889 g/mol
Full-length thymosin beta-443 residuesabout 4,960 g/mol

The fragment identity comes from analytical work on products sold as TB-500: Esposito and colleagues synthesised and characterised the N-terminally acetylated 17 to 23 fragment found in TB-500 (Drug Testing and Analysis, 2012), and Ho and colleagues built a doping-control method for it (Journal of Chromatography A, 2012). The two molecules differ more than fivefold in mass, so 10 mg of one is a very different number of molecules from 10 mg of the other, and research on the full protein does not automatically describe the fragment. The TB-500 in our blends and single vials is the seven-residue fragment, CAS 885340-08-9. When comparing vials from different suppliers, ask which molecule is in the vial; a certificate that confirms identity by mass spectrometry answers it.

What the Literature Has and Has Not Tested

The evidence behind these blends is the evidence for their separate components, and none of it is about the mixture.

  • No published study tests GLOW or KLOW. Searches of PubMed and ClinicalTrials.gov on 14 November 2026 return no trial, animal study or cell study of either blend as a mixture; the PubMed records naming all three of GHK, BPC-157 and TB-500 are narrative reviews.
  • The one combination study found no added effect. A 2026 rat study of Achilles tendon transection compared BPC-157, TB-500 and the two together in groups of eight; the authors reported that the combination "did not confer additional benefits compared to either agent alone" (Biçer et al., Joint Diseases and Related Surgery 2026).
  • Each component's literature is mostly preclinical. BPC-157, the TB-500 fragment and KPV have no published human efficacy trial; a handful of BPC-157 studies are registered on ClinicalTrials.gov, and none for KPV. GHK-Cu has the longest history, largely in cell culture and cosmetic formulation research.
  • A fixed ratio was never derived from data. The 50 + 10 + 10 + 10 split is a retail convention. No publication establishes it as an optimum for anything.

A reader comparing the two blends is therefore comparing compositions and documentation, not two bodies of evidence.

What a Measured KLOW Lot Looks Like

A blend certificate should measure each component, not report one number for the vial. This is what SideChain Analytics reported for a KLOW lot (report COA-2026-SC-02802, lot VPKL80100, 27 September 2026, HPLC-MS/MS):

ComponentLabel fillMeasured net massMeasured purity
GHK-Cu50 mg62.48 mg99.81%
KPV10 mg11.29 mg99.64%
TB-50010 mg11.02 mg99.62%
BPC-15710 mg10.72 mg99.59%
Total80 mg95.50 mg99.74%, average across 4 measured components

The laboratory reports four figures and no purity for the blend as a whole; the 99.74% is our average of the four, weighted by measured mass. The total is 119.4% of the 80 mg label claim, and the overfill is uneven: GHK-Cu came in 25% over its label and BPC-157 7% over, so the measured ratio is about 5.8 : 1 : 1.03 : 1.05 rather than the nominal 5 : 1 : 1 : 1. This report covers the four-component vial only and says nothing about a GLOW lot. It can be checked against the laboratory's own record from our certificates of analysis page, and the full certificate, with every field it reports, is walked through in the four-component blend's measured composition.

Purity is a ratio, so it says nothing about how much material is in the vial. A vial holding a third less peptide than its label can still report 99%. Net mass per component is the half of the data that tells you what you actually have, and it is the half most listings leave out.

Why a Blend Is Harder to Verify Than a Single Compound

A single-compound vial gives one main chromatographic peak. A blend gives one per component, and those peaks have to be separated and identified before any of them can be measured. Small peptides of similar polarity can co-elute, leaving the column together, and then a purity figure describes a mixture of peaks rather than one compound. Chromatographic purity also bounds peptide-related impurities only, as the pharmacopoeial method states, so it cannot by itself confirm that the right four molecules are present.

A blend report worth relying on therefore does four things:

  1. Identifies every component by mass spectrometry, not by retention time alone.
  2. Reports a net mass for each component, so the ratio can be checked against the label.
  3. Reports a purity for each component, not one figure for the vial.
  4. Names the laboratory and a report number the laboratory's own site can verify.

The analytical trade-offs of multi-component vials are covered in more depth in the analytical tradeoffs of a blend, and our peptide testing labs directory lists independent laboratories that will analyse a blend you send them.

Cost Per Component

Because the three shared components are identical in both vials, the price gap between them is the cost of the 10 mg of KPV. Our USD list prices in November 2026:

GHK-Cu + BPC-157 + TB-500 70mgGHK-Cu + KPV + BPC-157 + TB-500 80mgSame components bought singly
GHK-Cu 50 mgincludedincluded$39
BPC-157 10 mgincludedincluded$46
TB-500 10 mgincludedincluded$69
KPV 10 mgnot includedincluded$39
Total$71$84$154 (three components) / $193 (four)

The four-component vial costs $13 more for the same 10 mg of KPV that costs $39 on its own. The single compounds cost more and are the only option when a design needs to set each amount independently.

Where the Names Come From

The names are retail nicknames, not chemical names. "GLOW" became the market's name for the GHK-Cu, BPC-157 and TB-500 blend, and "KLOW" adds a K for KPV. Both grew out of the older two-component BPC-157 + TB-500 pairing, which we list by composition as BPC-157 + TB-500. Because the names are not standardised, two vials sold as KLOW can hold different ratios, which is why the per-component fill and a component-by-component certificate matter more than the name.

Choosing Between Them for a Research Design

  • The three-component blend suits a design that does not involve KPV, or where KPV would add a variable you would rather not control for.
  • The four-component blend suits a design that specifically calls for KPV alongside the other three at the fixed 50 + 10 + 10 + 10 ratio.
  • Single compounds suit any design where an amount or ratio has to vary, or where one component must be measured or controlled on its own.

Either way, confirm three things before ordering: the per-component fill, which TB-500 molecule is used, and whether the lot has a component-by-component report.

Regulatory Status in Canada and the United States

In Canada, none of the four components holds a Drug Identification Number or a Notice of Compliance, so none can be sold as a medicine. Health Canada's public advisory RA-81874 of 9 April 2026 names BPC-157, TB-500 and GHK-Cu among unauthorized peptide drugs and states that a research-use-only label does not make such products legal for human use. GHK-Cu is also a cosmetic ingredient under the INCI name copper tripeptide-1, which is a separate regulatory category from a lyophilised research vial. The framework is set out in are peptides legal in Canada.

In the United States, none of the four is an approved drug product. KPV was reviewed by the FDA's Pharmacy Compounding Advisory Committee in July 2026, and a draft HHS enforcement policy of 30 October 2026 that covers state-licensed compounding includes it; neither step is an approval, and neither applies to research material.

Both blends are supplied for laboratory research use only and are not for human use.

Frequently Asked Questions

What is the difference between GLOW and KLOW?

One component. GLOW contains GHK-Cu, BPC-157 and TB-500 at 50 + 10 + 10 mg. KLOW contains the same three plus 10 mg of KPV, for 80 mg in total.

What is the KLOW peptide blend?

A fixed-ratio research blend of four peptides: GHK-Cu, KPV, BPC-157 and TB-500, usually at 50 + 10 + 10 + 10 mg for 80 mg. The name is a retail nickname, so the composition should be read from the label or certificate.

What are GLOW peptides?

"GLOW" is the retail name for a three-peptide blend of GHK-Cu, BPC-157 and TB-500, usually 50 + 10 + 10 mg. It is unrelated to cosmetic products sold under similar names.

What is the difference between GLOW 70 and KLOW 80?

The numbers are the total label mass. GLOW 70 is 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500; KLOW 80 adds 10 mg of KPV.

Is GHK-Cu the same as GLOW?

No. GHK-Cu is one of GLOW's three components, and it makes up about 71% of the blend's mass. A single-compound GHK-Cu vial contains no BPC-157 or TB-500.

What does the K in KLOW stand for?

KPV, the tripeptide Lys-Pro-Val from the C-terminal end of alpha-MSH.

Why are GLOW and KLOW blue?

Because of the copper(II) complex in GHK-Cu, which dominates both vials. Copper(II) complexes absorb red light and look blue. The colour says nothing about the three colourless components.

Does the copper in GHK-Cu react with the other peptides?

It is not expected to move far. GHK binds copper(II) with very high affinity through a histidine-based site, and the other three components have no histidine to compete for it. None of them contains methionine, cysteine or tryptophan, the residues copper most readily oxidises.

What is the difference between copper gluconate and a copper peptide?

Copper gluconate is a simple copper salt of gluconic acid. A copper peptide such as GHK-Cu is copper held in a defined coordination site on a peptide, which changes how tightly the copper is bound and how it behaves in solution.

Which TB-500 is in these blends?

It depends on the supplier. "TB-500" is sold both as the seven-residue fragment Ac-LKKTETQ (889 g/mol) and as full-length thymosin beta-4 (about 4,960 g/mol). The TB-500 in our vials is the fragment, CAS 885340-08-9.

Has GLOW or KLOW been studied?

Not as a blend. No published study tests either mixture. The closest is a 2026 rat study of BPC-157 and TB-500 together, which reported no added effect over either compound alone.

How do I check what is really in a GLOW or KLOW vial?

Look for a report that identifies each component by mass spectrometry and gives each its own net mass and purity, from a laboratory whose site verifies the report number. A single purity figure for the whole vial mostly describes the GHK-Cu peak.

How much does KLOW cost compared with GLOW?

At our November 2026 list prices, the four-component vial costs $84 and the three-component vial $71, so the 10 mg of KPV adds $13.

Can the ratio in GLOW or KLOW be changed?

No. Both are fixed-ratio blends. Varying any one component means using the single compounds.

Sources

  • Dalmasso G, Charrier-Hisamuddin L, et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166-178. PMID 18061177.
  • Kannengiesser K, Maaser C, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease." Inflammatory Bowel Diseases. 2008;14(3):324-331. PMID 18092346.
  • Esposito S, Deventer K, et al. "Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential." Drug Testing and Analysis. 2012;4(9):733-738. PMID 22962027.
  • Ho EN, Kwok WH, et al. "Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry." Journal of Chromatography A. 2012;1265:57-69. PMID 23084823.
  • Trapaidze A, Hureau C, Bal W, et al. "Thermodynamic study of Cu2+ binding to the DAHK and GHK peptides by isothermal titration calorimetry (ITC) with the weaker competitor glycine." Journal of Biological Inorganic Chemistry. 2012;17(1):37-47. PMID 21898044.
  • Biçer O, Adanir O, et al. "Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study." Joint Diseases and Related Surgery. 2026;37(3):822-837. PMID 42542926.
  • Health Canada. Public advisory RA-81874 on unauthorized peptide products bought online, 9 April 2026.
  • US Department of Health and Human Services. "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Federal Register, 30 October 2026, FR Doc. 2026-22192.
  • SideChain Analytics. Certificate of analysis COA-2026-SC-02802, GHK-Cu + KPV + BPC-157 + TB-500 80mg, lot VPKL80100, 27 September 2026.
Research Use Only. This article is provided for informational and educational purposes only. The compounds and topics discussed are intended solely for laboratory and scientific research. This content does not constitute medical advice, and Volta Peptides does not endorse or promote human consumption of any research compound.

About the author

Marcus Hopkin, PhD, Director of Research and Development at Volta Peptides.

Marcus Hopkin, PhD

Director of Research and Development, Volta Peptides

Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.

Marcus wrote this article, last reviewed November 15, 2026. It is in-house scientific writing by a named member of staff and is not peer review, independent third-party review or medical advice.

Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.

Your Cart

Your cart is empty

Browse our catalog to add research compounds.